Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | SI | P14410 | 1/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005270 | 0.92 | GAA (0.54) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1617817 | 0.92 | GAA (0.54) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4997648 | 0.91 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10236626 | 0.91 | GAA (0.51) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2680543 | 0.91 | GAA (0.51) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL434421 | 0.90 | MGAM (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL8269713 | 0.88 | GAA (0.45) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4480984 | 0.88 | GAA (0.45) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13848940 | 0.87 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL6890748 | 0.87 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4691553-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-5075316-A | For plants | CIBA-GEIGY CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0444533-A2 | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-5032602-A | Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-16 | — | — | US | disclosed |
| US-5006530-A | Certain 7-[2,6-diisopropyl-4-phenyl-5-lower alkoxymethyl-pyrid-3-yl]-3,5-dihydroxy-6-enoates and derivatives useful for treating circulatory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-09 | — | — | US | disclosed |
| US-4968689-A | Certain 2,6-diisopropyl-4-(4-fluoro-phenyl)-3,5-bis-dimethyl-3',5'-dihydroxy-hept-6-enoate-pyridine derivatives useful for treating lipoproteinaemia and arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0388838-A2 | Parasiticide | CIBA-GEIGY AG (CH) | 1990-09-26 | — | — | EP | disclosed |
| US-4935434-A | Antiarthritic isoxazole-4-carboxamides | BRISTOL-MYERS COMPANY (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0326107-A1 | Antiarthritic beta-cycloalkyl-beta-oxopropionitriles | Bristol-Myers Squibb Company (US) | 1989-08-02 | — | — | EP | disclosed |
| EP-0326108-A1 | Antiarthritic isoxazole-4-carboxamides | Bristol-Myers Company (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4500541-A | Pharmacologically active cyclopropane derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | GAA 2438/4885MGAM 2346/4885SI 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.